{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:21:04Z","timestamp":1794352864841,"version":"4.9.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The porphyrias are a group of disorders of heme biosynthesis, each characterized by an enzymatic defect in the heme biosynthetic pathway. Porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress. Most patients with PCT have evidence of siderosis on liver biopsy, and the disease resolves with iron depletion. PCT manifests as skin fragility, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins. Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis. Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content. The following review explores the biology of PCT, the critical role of iron in disease pathogenesis, and our approach to the management of these patients.<\/jats:p>","DOI":"10.1182\/hematology.2024000664","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:04:33Z","timestamp":1733497473000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Porphyria cutanea tarda: a unique iron-related disorder"],"prefix":"10.1182","volume":"2024","author":[{"given":"Rebecca K.","family":"Leaf","sequence":"first","affiliation":[{"name":"1 Division of Hematology\/Oncology, Massachusetts General Hospital, Boston, MA"},{"name":"2 Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Dickey","sequence":"additional","affiliation":[{"name":"2 Harvard Medical School, Boston, MA"},{"name":"3 Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"9","key":"2024121115504463700_hem2024000664C1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2024121115504463700_hem2024000664C2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.V95.5.1565.005k42_1565_1571","article-title":"Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda","volume":"95","author":"Bulaj","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2024121115504463700_hem2024000664C3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2019.01.004","article-title":"Porphyria cutanea tarda: recent update","volume":"128","author":"Singal","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"13","key":"2024121115504463700_hem2024000664C4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJM198204013061302","article-title":"Decreased hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda","volume":"306","author":"Felsher","year":"1982","journal-title":"N Engl J Med"},{"issue":"6","key":"2024121115504463700_hem2024000664C5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM197808102990603","article-title":"Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda","volume":"299","author":"Elder","year":"1978","journal-title":"N Engl J Med"},{"issue":"1","key":"2024121115504463700_hem2024000664C6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-2007-1007142","article-title":"Porphyria cutanea tarda","volume":"18","author":"Elder","year":"1998","journal-title":"Semin Liver Dis"},{"issue":"3","key":"2024121115504463700_hem2024000664C7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00401245","article-title":"Assignment of human uroporphyrinogen decarboxylase (URO-D) to the p34 band of chromosome 1","volume":"73","author":"Dubart","year":"1986","journal-title":"Hum Genet"},{"issue":"18","key":"2024121115504463700_hem2024000664C8","doi-asserted-by":"crossref","first-page":"7343","DOI":"10.1093\/nar\/15.18.7343","article-title":"Structure of the gene for human uroporphyrinogen decarboxylase","volume":"15","author":"Romana","year":"1987","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"2024121115504463700_hem2024000664C9","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1093\/emboj\/cdg606","article-title":"Structural basis for tetrapyrrole coordination by uroporphyrinogen decarboxylase","volume":"22","author":"Phillips","year":"2003","journal-title":"EMBO J"},{"issue":"3","key":"2024121115504463700_hem2024000664C10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","article-title":"Heme biosynthesis and the porphyrias","volume":"128","author":"Phillips","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"11","key":"2024121115504463700_hem2024000664C11","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1182\/blood.V112.11.3454.3454","article-title":"The uroporphomethene inhibitor causitive for porphyria cutanea tarda (PCT) is generated by oxidation of hydroxymethylbilane (HMB)","volume":"112","author":"Phillips","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2024121115504463700_hem2024000664C12","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1073\/pnas.0700547104","article-title":"A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda","volume":"104","author":"Phillips","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2024121115504463700_hem2024000664C13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/bmc.860","article-title":"Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis by high-performance liquid chromatography\/ electrospray ionization tandem mass spectrometry","volume":"21","author":"Danton","year":"2007","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"2024121115504463700_hem2024000664C14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-2008-1040706","article-title":"Pathogenesis and treatment of photocutaneous manifestations of the porphyrias","volume":"2","author":"Poh-Fitzpatrick","year":"1982","journal-title":"Semin Liver Dis"},{"issue":"1","key":"2024121115504463700_hem2024000664C15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1073\/pnas.98.1.259","article-title":"A mouse model of familial porphyria cutanea tarda","volume":"98","author":"Phillips","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2024121115504463700_hem2024000664C16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3390\/diagnostics11081343","article-title":"Laboratory diagnosis of porphyria","volume":"11","author":"Di Pierro","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"2024121115504463700_hem2024000664C17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jcp.28.8.601","article-title":"Differentiation of porphyria cutanea tarda symptomatica from other types of porphyria by measurement of isocoproporphyrin in faeces","volume":"28","author":"Elder","year":"1975","journal-title":"J Clin Pathol"},{"issue":"7","key":"2024121115504463700_hem2024000664C18","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1021\/ac702130n","article-title":"Direct assay of enzymes in heme biosynthesis for the detection of porphyrias by tandem mass spectrometry. Uroporphyrinogen decarboxylase and coproporphyrinogen III oxidase","volume":"80","author":"Wang","year":"2008","journal-title":"Anal Chem"},{"issue":"3","key":"2024121115504463700_hem2024000664C19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2018.11.012","article-title":"Recent advances on porphyria genetics: inheritance, penetrance and molecular heterogeneity, including new modifying\/causative genes","volume":"128","author":"Yasuda","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"2024121115504463700_hem2024000664C20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.0954-6820.1971.tb04337.x","article-title":"The effect of phlebotomy therapy in porphyria cutanea tarda: its relation to the phlebotomy-induced reduction of iron stores","volume":"189","author":"Lundvall","year":"1971","journal-title":"Acta Med Scand"},{"issue":"2","key":"2024121115504463700_hem2024000664C21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.gastro.2010.06.013","article-title":"Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment","volume":"139","author":"Pietrangelo","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"2024121115504463700_hem2024000664C22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-2005-923317","article-title":"Iron in nonhemochromatotic liver disorders","volume":"25","author":"Alla","year":"2005","journal-title":"Semin Liver Dis"},{"issue":"12","key":"2024121115504463700_hem2024000664C23","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood-2008-02-138222","article-title":"Down-regulation of hepcidin in porphyria cutanea tarda","volume":"112","author":"Ajioka","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2024121115504463700_hem2024000664C24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcmd.2011.07.006","article-title":"Uroporphyria in the Cyp1a2-\/- mouse","volume":"47","author":"Phillips","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2024121115504463700_hem2024000664C25","doi-asserted-by":"crossref","first-page":"845852","DOI":"10.1016\/j.jhep.2009.06.027","article-title":"Reduced serum hepcidin levels in patients with chronic hepatitis C","volume":"51","author":"Girelli","year":"2009","journal-title":"J Hepatol"},{"issue":"9","key":"2024121115504463700_hem2024000664C26","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/jcmm.12310","article-title":"Role of duodenal iron transporters and hepcidin in patients with alcoholic liver disease","volume":"18","author":"Dostalikova-Cimburova","year":"2014","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2024121115504463700_hem2024000664C27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"issue":"2","key":"2024121115504463700_hem2024000664C28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","article-title":"Porphyria and kidney diseases","volume":"11","author":"Pallet","year":"2018","journal-title":"Clin Kidney J"},{"issue":"1","key":"2024121115504463700_hem2024000664C29","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1111\/j.1468-3083.2012.04511.x","article-title":"Increased serum hepcidin levels in patients with porphyria cutanea tarda","volume":"27","author":"Darwich","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2024121115504463700_hem2024000664C30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bpg.2010.07.002","article-title":"Porphyria cutanea tarda\u2014when skin meets liver","volume":"24","author":"Frank","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"2024121115504463700_hem2024000664C31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1013746828074","article-title":"Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency","volume":"47","author":"Egger","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"12","key":"2024121115504463700_hem2024000664C32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00109-022-02254-8","article-title":"Iron and iron-related proteins in alcohol consumers: cellular and clinical aspects","volume":"100","author":"Ferrao","year":"2022","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"2024121115504463700_hem2024000664C33","first-page":"277","article-title":"Alcohol, oxidative stress, and free radical damage","volume":"27","author":"Wu","year":"2003","journal-title":"Alcohol Res Health"},{"issue":"3","key":"2024121115504463700_hem2024000664C34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ymgme.2019.05.003","article-title":"Association between hepatitis C virus and porphyria cutanea tarda","volume":"128","author":"To-Figueras","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2024121115504463700_hem2024000664C35","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1007\/s10620-023-07859-8","article-title":"Ledipasvir\/sofosbuvir is effective as sole treatment of porphyria cutanea tarda with chronic hepatitis C","volume":"68","author":"Bonkovsky","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2024121115504463700_hem2024000664C36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archderm.1970.04000090022004","article-title":"Estrogen-induced porphyria cutanea tarda: report of three cases","volume":"102","author":"Roenigk","year":"1970","journal-title":"Arch Dermatol"},{"issue":"2","key":"2024121115504463700_hem2024000664C37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/abbi.1997.0306","article-title":"Release of iron from ferritin storage by redox cycling of stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen","volume":"346","author":"Wyllie","year":"1997","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2024121115504463700_hem2024000664C38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/0956462991912944","article-title":"Porphyria cutanea tarda and HIV\/AIDS: a review of pathogenesis, clinical manifestations and management","volume":"10","author":"Mansourati","year":"1999","journal-title":"Int J STD AIDS"},{"issue":"2","key":"2024121115504463700_hem2024000664C39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/clinids\/20.2.348","article-title":"Human immunodeficiency virus infection and porphyria cutanea tarda: coexistence of risk factors or causative association?","volume":"20","author":"McAlister","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2024121115504463700_hem2024000664C40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archderm.1980.01640260067017","article-title":"Porphyria cutanea tarda associated with chronic renal disease and hemodialysis","volume":"116","author":"Poh Fitzpatrick","year":"1980","journal-title":"Arch Dermatol"},{"key":"2024121115504463700_hem2024000664C41","first-page":"2017","article-title":"Porphyria cutanea tarda in a patient with end-stage renal disease: a case of successful treatment with deferoxamine and ferric carboxymaltose","author":"Rodrigues","year":"2017","journal-title":"Case Rep Nephrol"},{"issue":"2","key":"2024121115504463700_hem2024000664C42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000185945","article-title":"Plasma porphyrins in chronic renal failure","volume":"55","author":"Gebril","year":"1990","journal-title":"Nephron"},{"issue":"2","key":"2024121115504463700_hem2024000664C43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archderm.1970.04000020037006","article-title":"Phlebotomy therapy in cutaneous porphyria: effect on iron and trace metals","volume":"101","author":"Walsh","year":"1970","journal-title":"Arch Dermatol"},{"issue":"12","key":"2024121115504463700_hem2024000664C44","first-page":"1377","article-title":"Health care utilization and economic burdens of hemochromatosis in the United States: a population-based claims study","volume":"25","author":"Elsaid","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"2024121115504463700_hem2024000664C45","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","article-title":"Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda","volume":"10","author":"Singal","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024121115504463700_hem2024000664C46","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-67002-2_21","article-title":"Chloroquine in the treatment of porphyria cutanea tarda","volume-title":"Diagnosis and Therapy of Porphyrias and Lead Intoxication","author":"Kordac","year":"1978"},{"issue":"8","key":"2024121115504463700_hem2024000664C47","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/0961203318768884","article-title":"The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda","volume":"27","author":"Sunkara","year":"2018","journal-title":"Lupus"},{"issue":"5","key":"2024121115504463700_hem2024000664C48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJM199002013220507","article-title":"Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis","volume":"322","author":"Anderson","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"2024121115504463700_hem2024000664C49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000247732","article-title":"Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda","volume":"182","author":"Rocchi","year":"1991","journal-title":"Dermatologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/450\/2346448\/450leaf.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/450\/2346448\/450leaf.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:22:06Z","timestamp":1733948526000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/450\/526222\/Porphyria-cutanea-tarda-a-unique-iron-related"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000664","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}